D
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
D. Bhadra's research focuses on the development and application of drug delivery systems, particularly polymer-based nanoparticles and dendrimers. Their work investigates methods for producing these nanoparticles and assessing their drug stability and release characteristics. Publications include studies on the clinical relevance of animal models for lymphatic dysfunction and lymphedema, and the comparative efficacy of novel androgen receptor inhibitors for prostate cancer. Bhadra has also contributed to meta-analyses and systematic reviews evaluating cancer treatments. Their research network includes collaborators such as Amanda J. Stolarz, Pritam Saha Podder, and Soumiya Pal, all affiliated with the University of Arkansas for Medical Sciences. Bhadra has published 23 works, with an h-index of 12 and over 1,500 citations.
Metrics
- h-index: 12
- Publications: 23
- Citations: 1,562
Selected Publications
-
Clinical Relevance of Animal Models of Lymphatic Dysfunction and Lymphedema (2025)
Collaboration Network
Top Collaborators
Gargi Baluni
2 shared publications
- EE349 Cost-Effectiveness of First-Line Treatment With Pembrolizumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer (CRC) in the United States Based on 5-Year Follow-up Data
- CO99 Validation of Overall Survival (OS) Extrapolations Using 5-Year Follow-up Data From the Keynote-177 MSI-H/dMMR Metastatic Colorectal Cancer (mCRC) Study
Ruifeng Xu
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
2 shared publications
- EE349 Cost-Effectiveness of First-Line Treatment With Pembrolizumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer (CRC) in the United States Based on 5-Year Follow-up Data
- CO99 Validation of Overall Survival (OS) Extrapolations Using 5-Year Follow-up Data From the Keynote-177 MSI-H/dMMR Metastatic Colorectal Cancer (mCRC) Study
Rachid Massaad
MSD (Belgium) (BE)
2 shared publications
- EE349 Cost-Effectiveness of First-Line Treatment With Pembrolizumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer (CRC) in the United States Based on 5-Year Follow-up Data
- CO99 Validation of Overall Survival (OS) Extrapolations Using 5-Year Follow-up Data From the Keynote-177 MSI-H/dMMR Metastatic Colorectal Cancer (mCRC) Study
Gerard McCarthy
MSD (UK) Limited (United Kingdom) (GB)
1 shared publication
- EE349 Cost-Effectiveness of First-Line Treatment With Pembrolizumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer (CRC) in the United States Based on 5-Year Follow-up Data
Neeraj Chhabra
1 shared publication
- EE349 Cost-Effectiveness of First-Line Treatment With Pembrolizumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer (CRC) in the United States Based on 5-Year Follow-up Data
M Chaudhuri
1 shared publication
- EE349 Cost-Effectiveness of First-Line Treatment With Pembrolizumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer (CRC) in the United States Based on 5-Year Follow-up Data
Mayur M. Amonkar
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
1 shared publication
- EE349 Cost-Effectiveness of First-Line Treatment With Pembrolizumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer (CRC) in the United States Based on 5-Year Follow-up Data
Grant McCarthy
MSD (UK) Limited (United Kingdom) (GB)
1 shared publication
- CO99 Validation of Overall Survival (OS) Extrapolations Using 5-Year Follow-up Data From the Keynote-177 MSI-H/dMMR Metastatic Colorectal Cancer (mCRC) Study
Navika Chhabra
1 shared publication
- CO99 Validation of Overall Survival (OS) Extrapolations Using 5-Year Follow-up Data From the Keynote-177 MSI-H/dMMR Metastatic Colorectal Cancer (mCRC) Study
M. Chaudhuri
1 shared publication
- CO99 Validation of Overall Survival (OS) Extrapolations Using 5-Year Follow-up Data From the Keynote-177 MSI-H/dMMR Metastatic Colorectal Cancer (mCRC) Study
M. Amonkar
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
1 shared publication
- CO99 Validation of Overall Survival (OS) Extrapolations Using 5-Year Follow-up Data From the Keynote-177 MSI-H/dMMR Metastatic Colorectal Cancer (mCRC) Study
Pritam Saha Podder
University of Arkansas for Medical Sciences
1 shared publication
In database
- Clinical Relevance of Animal Models of Lymphatic Dysfunction and Lymphedema
Soumiya Pal
University of Arkansas for Medical Sciences
1 shared publication
In database
- Clinical Relevance of Animal Models of Lymphatic Dysfunction and Lymphedema
V. Suzanne Klimberg
The University of Texas Medical Branch at Galveston (US)
1 shared publication
- Clinical Relevance of Animal Models of Lymphatic Dysfunction and Lymphedema
Amanda J. Stolarz
University of Arkansas for Medical Sciences
1 shared publication
In database
- Clinical Relevance of Animal Models of Lymphatic Dysfunction and Lymphedema
Similar Researchers
Based on overlapping research topics
Arisha Ishtiaq
University of Arkansas at Little Rock
Nanoparticle-Based Drug Delivery
Drug Delivery Systems
Cancer Treatment and Pharmacology
Zachary McConnell
University of Arkansas at Fayetteville
Nanoparticle-Based Drug Delivery
Drug Delivery Systems
Cancer Treatment and Pharmacology
Nabeel Alwan
University of Arkansas at Little Rock
Nanoparticle-Based Drug Delivery
Drug Delivery Systems
Cancer Treatment and Pharmacology
David Fugitt
University of Arkansas at Fayetteville
Nanoparticle-Based Drug Delivery
Drug Delivery Systems
Cancer Treatment and Pharmacology
Christopher Salmon
University of Arkansas at Fayetteville
Nanoparticle-Based Drug Delivery
Drug Delivery Systems
Cancer Treatment and Pharmacology
Joseph Batta‐Mpouma
University of Arkansas at Fayetteville
Nanoparticle-Based Drug Delivery
Drug Delivery Systems
Cancer Treatment and Pharmacology